Table 2.
Summary of Reasons for Isavuconazole Discontinuation and Invasive Fungal Infection Outcomes After the 30-Day Follow-up Period
| Reason for Discontinuation of ISAV | Total | IFI Outcome 30 d After the Last Dose of ISAV | |||
|---|---|---|---|---|---|
| No. (%) | No IFI | Possible IFI | Probable IFI | Proven IFI | |
| Completed 12 wk of ISAV | 9 (14) | 9 | 0 | 0 | 0 |
| Achieved CR/CRi + ANC > 0.5 | 37 (57) | 36 | 0 | 0 | 1 |
| Investigator decision | 7 (11) | 6 | 1 | 0 | 0 |
| Death, not IFI-related | 2 (3) | NA (2) | NA | NA | NA |
| Possible IFI | 8 (12) | 0 | 7 | 1 | 0 |
| Probable IFI | 2 (3) | 0 | 0 | 2 | 0 |
| All patients, no. (%) | … | 53 (82) | 8 (12) | 3 (5) | 1 (2) |
Patients with a change in their IFI classification during the follow-up period are highlighted in bold.
Abbreviations: ANC, absolute neutrophil count; CR/CRi, complete remission with our without complete count recovery; IFI, invasive fungal infection; ISAV, isavuconazole; NA, not applicable.